AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03231735 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard frequency ventilation
Description: Mechanical ventilator used at rates \< 60 per minute and ≥ 20 per minute, with patient triggered ventilation and pressure support.
Study NCT04600089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline infusion
Study NCT04600089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Continuous ketamine infusion at a dose of 0.2 mg/kg/hr, initiated at the induction of anesthesia and continued for 48 hours postoperatively.
Study NCT02943031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized Precision Therapy Programs
Description: After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided according to the different genomics classification.OS and PFS will be recorded.
Study NCT02329821 — intervention group
Intervention type: OTHER
Intervention: hartmann solution
Description: hartmann solution infusion in patients for hepatic resection
Study NCT01461083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MPPF
Description: Subjects will be dosed by intravenous bolus injection of \[18F\]MPPF targeted to be 5.0 mCi, and not to exceed 5.5 mCi (not >10% of 5.0 mCi limit) and not to exceed 5 µg of MPPF
Study NCT04390061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Jak-1/3 inhibitor
Study NCT04390061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Standard Therapy
Study NCT04390061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Standard Therapy
Study NCT01336296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolic acid
Description: Comparing mycophenolic acid 720mg orally twice daily starting 2 weeks prior to transplant to mycophenolic acid 720mg orally twice daily starting day of transplant.
Study NCT02209831 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIBR 796 BS
Description: single dose
Study NCT02209831 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIBR 796 BS
Description: single dose
Study NCT02209831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 5 days
Study NCT01140373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: engineered autologous T cells
Description: Three cohorts of patients each will receive escalating doses of transduced autologous chimeric T lymphocytes at 1 x 10\^7 CAR+ T cells/kg, 3 x 10\^7 CAR+ T cells/kg, and 1 x 108 CAR+ T cells/kg, respectively. One patient will be initially added to the three already enrolled in cohort 1 using a new variant vector expressing the P28z CAR, and up to three patients may be added to each cohort, for a total of up to six each, in the case of Grade 3 toxicity and/or sub-optimal imaging. A 4th cohort of three patients may be added if an anti-PSMA effect is observed either immunologically or radiographically or if there is preferential targeting of the cells at a particular dose level. The dose level of the 4th cohort would be from a previously tested dose level. All patients will receive one dose of cyclophosphamide (Cy) at 300mg/m2 iv one day prior to infusion of T cells.
Study NCT01140373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Three cohorts of patients each will receive escalating doses of transduced autologous chimeric T lymphocytes at 1 x 10\^7 CAR+ T cells/kg, 3 x 10\^7 CAR+ T cells/kg, and 1 x 10\^8 CAR+ T cells/kg, respectively. One patient will be initially added to the three already enrolled in cohort 1 using a new variant vector expressing the P28z CAR, and up to three patients may be added to each cohort, for a total of up to six each, in the case of Grade 3 toxicity and/or sub-optimal imaging. A 4th cohort of three patients may be added if an anti-PSMA effect is observed either immunologically or radiographically or if there is preferential targeting of the cells at a particular dose level. The dose level of the 4th cohort would be from a previously tested dose level. All patients will receive one dose of cyclophosphamide (Cy) at 300mg/m2 iv one day prior to infusion of T cells.
Study NCT03987776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory energy-restricted diet
Description: During 6 months the participants will we asked to use recommended energy-reduced diet with anti-inflammatory properties, based on colorful vegetables and fruits, legumes, nuts, seeds, marine fish, whole-grain products, and daily use of olive oil, green/black tea, multiple spices and herbs.
Study NCT03987776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control energy-restricted diet
Description: During 6 months the participants of control group will be asked to use recommended energy-reduced diet based on standard obesity management (55-60% carbohydrates, 25% fat, 15-20% protein)
Study NCT04228393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine
Description: 6-mercaptopurine was administered orally to patients once daily.
Study NCT04228393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6-mercaptopurine
Description: 6-mercaptopurine was administered orally to patients once daily.
Study NCT04228393 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: The initial dose is 50mg/m2. The dose was adjusted according to white blood cells.
Study NCT04228393 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized treatment
Description: The initial dose is determined according to the genotypes of patients combined with Clinical Pharmacogenetics Implementation Consortium (CPIC). The dose was adjusted according to white blood cells, genotypes and the concentrations of 6-TGN in red blood cells.
Study NCT04493580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iDBT
Description: Electronic DBT sessions designed to mirror in-person DBT.
Study NCT04493580 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-Person DBT
Description: In-person DBT
Study NCT00496223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib will be given PO once daily on days 1-14 of each 21 day cycle. The exact dose of sunitinib will be determined during the Phase I part of the trial.
Study NCT00496223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine will be given at 1000 mg/m2 on day 1 of every 21 day cycle.
Study NCT03174249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Description: Daily training at an in-patient ward during four plus four weeks, separated by a home training period of 6-8 weeks.
Study NCT04228783 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: Participants will receive IM injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5\*10\^10 vp, Lot A, B, and C) on Day 1 (Groups 1, 2, 3 and 5) and an Ad26.ZEBOV booster dose on Day 177 (Group 5).
Study NCT04228783 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: Participants will receive IM injection (0.5 mL) of MVA-BN-Filo as Dose 2 (1\*10\^8 Inf U, Lot 1, 2, 3 and 5) on Day 57.
Study NCT04228783 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive IM injection (0.5 mL) of placebo (0.9 % saline) as Dose 1 on Day 1, followed by placebo as Dose 2 on Day 57 (Groups 4 and 6) and a booster of matching placebo on Day 177 (Group 6).
Study NCT05430321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of physiological parameters
Description: FT implementation begins 3 minutes before the procedures and 10 minutes continuous. After the end of the procedures further 3 minutes was given . Physiological parameters were simultaneously recorded on the registration form
Study NCT05430321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of Stress
Description: Newborn Stress Scale (NSS) was used end of the all procedures which means 13th minute.
Study NCT03038451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-NOR (s-amlodipine) 2,5 mg & 5 mg tablet
Study NCT02907268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: onabotulinumtoxinA
Description: OnabotulinumtoxinA (Botox; Allergan) was approved by the FDA in 2002. Intervention administered by study nurse. Intradermal administered in a regular 1 cm2 grid across the cheeks and forehead. Intramuscular administered as per normal practice.
Study NCT01639664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High doses CPFA
Description: High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): >0.20 L/kg/day of plasma treated in the first 3 days after randomization.
Study NCT01924364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Genesis Cell Isolation System™ (TGI CIS)
Description: In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be processed by the Tissue Genesis Cell Isolation System™ (CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient. Additionally, data from our current study assessing volume retention after fat grafting for facial deformities (IRB # PRO09060101, NCT01345591) will be used for comparison.
Study NCT01924364 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard of care fat grafting
Description: In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time.
Study NCT02966340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: 2mg Prazosin
Study NCT02966340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT01360216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LARC education and training
Description: A CME/CEU accredited Grand Rounds education and training session will be given to clinicians and contraceptive educators practicing in clinics assigned to the intervention arm. Clinicians will have hands-on training as well. The half-day session emphasizes evidence-based contraceptive counseling and provision.
Study NCT02907268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abobotulinumtoxinA
Description: AbobotulinumtoxinA (Dysport; Galderma) was approved by the FDA in 2009. Intervention administered by study nurse. Intradermal administered in a regular 1 cm2 grid across the cheeks and forehead. Intramuscular administered as per normal practice.
Study NCT01358773 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: multidisciplinary intervention
Description: Comparison of the polysomnography results, blood collection parameters, resting metabolic rate values, body composition variables, carotid artery thickness values, abdominal and subcutaneous fat and lung function variables baseline, middle and at the end of the one year of interdisciplinary weight loss program combined exercise training with physiotherapy, clinical, nutritional and psychological therapies.
Study NCT03071146 — intervention group
Intervention type: DEVICE
Intervention: Bard® LifeStent® 5F Vascular Stent System
Description: The LifeStent® Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 - 6.5 mm.
Study NCT03210623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stent retriever(TonbridgeMT)
Description: mechanical thrombectomy with stent retriever(TonbridgeMT), digital subtraction angiography(DSA), computed tomography(CT), magnetic resonance imaging (MRI), diffusion weighted imaging (DWI)
Study NCT03210623 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Solitaire™
Description: mechanical thrombectomy with Solitaire™ , digital subtraction angiography(DSA), computed tomography(CT), magnetic resonance imaging(MRI), diffusion weighted imaging(DWI)
Study NCT03352479 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Opioid Return
Description: Calculate the percentage of prescribed to returned opioids
Study NCT05430321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of Comfort
Description: Neonatal Comfort Behavior Scale (NCBS) was used end of the all procedures which means 13th minute.
Study NCT03709472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Assisted CIFFTA
Description: This is a hybrid intervention that includes individual work with the adolescent (e.g., Motivational Interviewing, diary card identification of triggers), computer assisted psychoeducational work, and intensive family therapy interventions.
Study NCT03825523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iART
Description: After group assignment, ART will be started within the first 48 hours after admission to the hospital. ART regimen will be decided according to each subject´s the clinical characteristics
Study NCT03825523 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cART
Description: After group assignment, ART is started at the discretion of the attending physician. ART regimen will be decided according to each subject´s the clinical characteristics
Study NCT04375618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RhEGF
Description: The EGF impregnated membrane will be placed upon the recession site and will be stabilized by suturing it to the lingual papillae using 4-0 absorbable sutures. The flap will be coronally advanced as far as possible to cover the membrane and will be sutured to the buccal interdental papillae with 4-0 absorbable sutures (Trulenetm, Healthium Medtech Pvt Ltd, Bangalore, India). Standard recall and maintenance regimen will be followed and subjects will be encouraged to report to the department on a monthly basis.
Study NCT04375618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plain Collagen
Description: A collagen membrane without FGF-2 will be used.
Study NCT04377243 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: V8
Description: one pill per day either V8 or placebo
Study NCT04377243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V8
Description: one pill per day either V8 or placebo
Study NCT00678340 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WACA and PVI
Description: Wide area circumferential ablation (WACA) in the pulmonary vein antrum with subsequent pulmonary vein isolation (PVI) with a single tip irrigated catheter.
Study NCT00678340 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVAC
Description: Circumferential ablation with a circular ablation catheter (Ablation Frontiers) to electrical silence.
Study NCT02217709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenelzine sulfate
Description: Given by mouth
Study NCT02217709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02217709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT03113357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release technique
Description: myofascial release technique take along about 3 minutes. This phase repeated 3 times in each session. At the end, for more release, sub-occipital traction will commence. The subject lies supine with head supported and therapist places the three middle fingers just caudal to the nuchal line, lifts the finger tips upward resting the hands on the treatment table, and then applies a gentle cranial pull, causing a long axis extension. The procedure is performed for 2 to 3 minutes. Subjects in each group received ten physical therapy treatment sessions. Treatment frequency was six times per week for MFR group and every day for exercise group which three times per week have been come to clinical center for checking of exercise by physiotherapist
Study NCT03113357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional exercise therapy
Description: All exercises were performed to a count of 7 seconds and subjects were instructed to perform all exercises daily, 15 repetitions each (twice a day). Treatment frequency was every day for exercise group which three times per week have been come to clinical center for checking of exercise by physiotherapist. They also could be taught active muscle stretching exercises to address any muscle tightness assessed to be present.
Study NCT01610024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot Juice
Description: Give subjects 500ml beetroot juice in the 24 hour period prior to class begins. They will receive this during 3 of the 6 weeks
Study NCT01634854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Misoprostol
Description: Dosage: 25 µg every 4 hours up to a maximum of 4 doses until cervical change is consistent with a diagnosis of active labor Route of administration: Intravaginal
Study NCT01634854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Oxytocin
Description: Dosage: 2 miu per minute increased in increments of 1-2 miu per minute every 30 minutes to establish an effective contraction pattern.~Route of administration: intravenous
Study NCT03699254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Description: Valganciclovir is a L-valyl ester of ganciclovir that exists as a mix of 2 diastereomers. After administration, both are converted to ganciclovir by esterases. Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate.
Study NCT03699254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Valganciclovir is a L-valyl ester of ganciclovir that exists as a mix of 2 diastereomers. After administration, both are converted to ganciclovir by esterases. Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate.
Study NCT03699254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganciclovir
Description: Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate.
Study NCT03699254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Description: Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate.
Study NCT06713785 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amlodipine
Description: Amlodipine 1mg/ml Oral Solution
Study NCT03709472 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: Traditional face-to-face treatment-no technology
Description: Community agencies provide mostly individual counseling but may add some family involvement in treatment planning.
Study NCT00128141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tactile stimulus
Description: four times a day
Study NCT02191124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Patients in both groups (MBC or ST) receive open-label paroxetine (20-60mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China.
Study NCT02191124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Patients in both groups (MBC or ST) receive open-label paroxetine (20-60mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China.
Study NCT02191124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: Patients in both groups (MBC or ST) receive open-label mirtazapine (15-45mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China
Study NCT02191124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Patients in both groups (MBC or ST) receive open-label mirtazapine (15-45mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China